Open an account

KALA BIO

KALA · NASDAQ

$0.1897−$0.0029 (−1.51%)TodayMarket closed ·
Prev close $0.1926

About KALA

Kala Bio, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2017-07-20. The firm is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The firm is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

Employees
6
Headquarters
Arlington, Massachusetts
Listed
Jul 20, 2017
Sector
Health Care
Industry
Biotechnology
Website
kalarx.com

KALA key statistics

Market cap
3.67M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.66M
Volume
350.20K
Open price
$0.198
High today
$0.21
Low today
$0.1858
52 Week high
$95.50
52 Week low
$0.1146

KALA BIO (KALA) at a glance

KALA BIO (KALA) last traded at $0.1897, with a market cap of 3.67M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.1858 and $0.21. The current price is 2.1% above the day's low and 9.7% below its high.

Volume so far is 350.20K shares, below the average of 3.66M shares a day.

Over the past year KALA BIO has ranged from $0.1146 to $95.50, and now sits 0% of the way up that range.

KALA BIO met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q4 FY25 it reported -$33.50 per share against an estimate of -$73.44.

KALA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 29.5% on average.

  1. Q1 FY24: reported -$209.50 per share against an estimate of -$147.39
  2. Q2 FY24: reported -$158.00 per share against an estimate of -$224.65
  3. Q3 FY24: reported -$96.50 per share against an estimate of -$123.93
  4. Q4 FY24: reported -$87.00 per share against an estimate of -$116.28
  5. Q1 FY25: reported -$70.50 per share against an estimate of -$103.53
  6. Q2 FY25: reported -$85.50 per share against an estimate of -$86.87
  7. Q3 FY25: reported -$43.00 per share against an estimate of -$73.72
  8. Q4 FY25: reported -$33.50 per share against an estimate of -$73.44

KALA news

  • Tanya Rawat

    KALA Bio (KALA) Shares Soar 57% After Hours: Here's Why

  • Avi Kapoor

    Dow Dips Over 300 Points; Medtronic Shares Gain After Upbeat Q1 Earnings

  • Vandana Singh

    EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Crude Oil Gains Over 5%; US Inflation Holds Steady At 2.4%

  • Press releaseGlobe Newswire

    AI Platforms, Data Infrastructure, and Healthcare Innovation Shape the Market Narrative

  • Avi Kapoor

    US Stocks Mixed; Dow Falls 300 Points

  • Vandana Singh

    Kala Bio Chases 'Palantir For Biotech' Dream With New AI Platform

Similar companies

Companies in the same industry as KALA BIO

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.